{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:07:12Z","timestamp":1792145232526,"version":"4.4.0"},"reference-count":258,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T00:00:00Z","timestamp":1633478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Neurosci."],"abstract":"<jats:p>\n                    In recent years, gene therapy has been raising hopes toward viable treatment strategies for rare genetic diseases for which there has been almost exclusively supportive treatment. We here review this progress at the pre-clinical and clinical trial levels as well as market approvals within diseases that specifically affect the brain and spinal cord, including degenerative, developmental, lysosomal storage, and metabolic disorders. The field reached an unprecedented milestone when Zolgensma\u00ae (onasemnogene abeparvovec) was approved by the FDA and EMA for\n                    <jats:italic>in vivo<\/jats:italic>\n                    adeno-associated virus-mediated gene replacement therapy for spinal muscular atrophy. Shortly after EMA approved Libmeldy\u00ae, an\n                    <jats:italic>ex vivo<\/jats:italic>\n                    gene therapy with lentivirus vector-transduced autologous CD34-positive stem cells, for treatment of metachromatic leukodystrophy. These successes could be the first of many more new gene therapies in development that mostly target loss-of-function mutation diseases with gene replacement (e.g., Batten disease, mucopolysaccharidoses, gangliosidoses) or, less frequently, gain-of-toxic-function mutation diseases by gene therapeutic silencing of pathologic genes (e.g., amyotrophic lateral sclerosis, Huntington's disease). In addition, the use of genome editing as a gene therapy is being explored for some diseases, but this has so far only reached clinical testing in the treatment of mucopolysaccharidoses. Based on the large number of planned, ongoing, and completed clinical trials for rare genetic central nervous system diseases, it can be expected that several novel gene therapies will be approved and become available within the near future. Essential for this to happen is the in depth characterization of short- and long-term effects, safety aspects, and pharmacodynamics of the applied gene therapy platforms.\n                  <\/jats:p>","DOI":"10.3389\/fnmol.2021.695937","type":"journal-article","created":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T07:22:09Z","timestamp":1633591329000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":83,"title":["Current and Future Prospects for Gene Therapy for Rare Genetic Diseases Affecting the Brain and Spinal Cord"],"prefix":"10.3389","volume":"14","author":[{"given":"Thomas Leth","family":"Jensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casper Ren\u00e9","family":"G\u00f8tzsche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P. D.","family":"Woldbye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1089\/hum.2005.16.741","article-title":"Stability of lentiviral-mediated transgene expression in the brain in the presence of systemic antivector immune responses","volume":"16","author":"Abordo-Adesida","year":"2005","journal-title":"Hum. Gene Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/mt.2013.25","article-title":"Gene therapy for Canavan's disease takes a step forward","volume":"21","author":"Ahmed","year":"2013","journal-title":"Mol. Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1016\/j.ymthe.2020.04.007","article-title":"RNAi-based gene therapy rescues developmental and epileptic encephalopathy in a genetic mouse model","volume":"28","author":"Aimiuwu","year":"2020","journal-title":"Mol. Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1056\/NEJMoa0805817","article-title":"Gene therapy for immunodeficiency due to adenosine deaminase deficiency","volume":"360","author":"Aiuti","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"737","DOI":"10.15252\/emmm.201707573","article-title":"Gene therapy for ADA-SCID the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products","volume":"9","author":"Aiuti","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/ppul.24203","article-title":"Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy","volume":"54","author":"Al-Zaidy","year":"","journal-title":"Pediatr. Pulmonol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3233\/JND-190403","article-title":"AVXS-101 (onasemnogene abeparvovec) for SMA1: comparative study with a prospective natural history cohort","volume":"6","author":"Al-Zaidy","year":"","journal-title":"J. Neuromuscul. Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.04.008.","article-title":"Gene therapy for ALS: a review","author":"Amado","year":"2021","journal-title":"Mol. Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.ymthe.2018.11.013","article-title":"AAV-mediated progranulin delivery to a mouse model of progranulin deficiency causes T cell-mediated toxicity","volume":"27","author":"Amado","year":"2019","journal-title":"Mol. Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1523\/JNEUROSCI.3081-17.2018","article-title":"Progranulin gene therapy improves lysosomal dysfunction and microglial pathology associated with frontotemporal dementia and neuronal ceroid lipofuscinosis","volume":"38","author":"Arrant","year":"2018","journal-title":"J. Neurosci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3233\/JPD-181331","article-title":"Gene therapy for Parkinson's disease, an update","volume":"8","author":"Axelsen","year":"2018","journal-title":"J. Parkinsons Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/nature05016","article-title":"Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17","volume":"442","author":"Baker","year":"2006","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000503831","article-title":"The epidemiology of epilepsy","volume":"54","author":"Beghi","year":"2020","journal-title":"Neuroepidemiology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.2174\/138161208784705504","article-title":"Lysosomal storage diseases and the blood-brain barrier","volume":"14","author":"Begley","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"B15","doi-asserted-by":"publisher","first-page":"100604","DOI":"10.1016\/j.ymgmr.2020.100604","article-title":"Intravenous delivery for treatment of mucopolysaccharidosis type I: a comparison of AAV serotypes 9 and rh10","volume":"24","author":"Belur","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"key":"B16","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJM199403033300901","article-title":"A controlled trial of riluzole in amyotrophic lateral sclerosis","volume":"330","author":"Bensimon","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.omtm.2020.04.001","article-title":"Intra-CSF AAV9 and AAVrh10 administration in nonhuman primates: promising routes and vectors for which neurological diseases?","volume":"17","author":"Bey","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1016\/j.ymthe.2017.05.017","article-title":"A new AAV10-U7-mediated gene therapy prolongs survival and restores function in an ALS mouse model","volume":"25","author":"Biferi","year":"2017","journal-title":"Mol. Ther"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1233158","DOI":"10.1126\/science.1233158","article-title":"Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy","volume":"341","author":"Biffi","year":"2013","journal-title":"Science"},{"key":"B20","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1126\/science.270.5235.475","article-title":"T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years","volume":"270","author":"Blaese","year":"1995","journal-title":"Science"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1126\/science.1178811","article-title":"Breaking the code of DNA binding specificity of TAL-type III effectors","volume":"326","author":"Boch","year":"2009","journal-title":"Science"},{"key":"B22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1089\/hum.2015.122","article-title":"Therapeutic rAAVrh10 mediated SOD1 silencing in adult SOD1G93A mice and nonhuman primates","volume":"27","author":"Borel","year":"2016","journal-title":"Hum. Gene Ther"},{"key":"B23","doi-asserted-by":"publisher","first-page":"eaau6414","DOI":"10.1126\/scitranslmed.aau6414","article-title":"Safe and effective superoxide dismutase 1 silencing using artificial microRNA in macaques","volume":"10","author":"Borel","year":"2018","journal-title":"Sci. Transl. Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"9669","DOI":"10.1523\/JNEUROSCI.1635-16.2016","article-title":"Self-complementary AAV9 gene delivery partially corrects pathology associated with juvenile neuronal ceroid lipofuscinosis (CLN3)","volume":"36","author":"Bosch","year":"2016","journal-title":"J. Neurosci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"135841","DOI":"10.1016\/j.neulet.2021.135841","article-title":"Krabbe disease: new hope for an old disease","volume":"752","author":"Bradbury","year":"2021","journal-title":"Neurosci. Lett."},{"key":"B26","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1089\/hum.2017.151","article-title":"AAVrh10 gene therapy ameliorates central and peripheral nervous system disease in canine globoid cell leukodystrophy (Krabbe disease)","volume":"29","author":"Bradbury","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41591-019-0674-1","article-title":"Spinal subpial delivery of AAV9 enables widespread gene silencing and blocks motoneuron degeneration in ALS","volume":"26","author":"Bravo-Hernandez","year":"2020","journal-title":"Nat. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1146\/annurev-biochem-013118-111518","article-title":"Lysosomal glycosphingolipid storage diseases","volume":"88","author":"Breiden","year":"2019","journal-title":"Annu. Rev. Biochem."},{"key":"B29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s42466-020-00075-z","article-title":"Gene specific therapies \u2013 the next therapeutic milestone in neurology","volume":"2","author":"Brenner","year":"2020","journal-title":"Neurol. Res. Pract."},{"key":"B30","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/nrneurol.2016.133","article-title":"Angelman syndrome \u2013 insights into a rare neurogenetic disorder","volume":"12","author":"Buiting","year":"2016","journal-title":"Nat. Rev. Neurol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"5820","DOI":"10.1038\/s41467-020-19505-2","article-title":"The once and future gene therapy","volume":"11","author":"Bulaklak","year":"2020","journal-title":"Nat. Comm."},{"key":"B32","doi-asserted-by":"publisher","first-page":"68","DOI":"10.2174\/1566523218666180404162622","article-title":"Genetics and therapies for GM2 gangliosidosis","volume":"18","author":"Cachon-Gonzalez","year":"2018","journal-title":"Curr. Gene Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1016\/j.ymthe.2019.06.015","article-title":"Gene therapy corrects brain and behavioral pathologies in CLN6-Batten disease","volume":"27","author":"Cain","year":"2019","journal-title":"Mol. Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41409-020-01119-3","article-title":"Lentiviral hematopoietic stem and progenitor cell gene therapy (HSPC-GT) for metachromatic leukodystrophy (MLD): clinical outcomes from 33 patients. The 46th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Oral Session (O010\u2013O173)","volume":"55","author":"Calbi","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"B35","doi-asserted-by":"publisher","first-page":"4388","DOI":"10.3390\/ijms20184388","article-title":"Gene therapy for ALS\u2014a perspective","volume":"20","author":"Cappella","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B36","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1126\/science.1171242","article-title":"Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy","volume":"326","author":"Cartier","year":"2009","journal-title":"Science"},{"key":"B37","doi-asserted-by":"publisher","first-page":"608001","DOI":"10.3389\/fnmol.2020.608001","article-title":"NPY and gene therapy for epilepsy: how, when,. and Y","volume":"13","author":"Cattaneo","year":"2021","journal-title":"Front. Mol. Neurosci"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1182\/blood-2007-01-068959","article-title":"Hot spots of retroviral integration in human CD34+ hematopoietic cells","volume":"110","author":"Cattoglio","year":"2007","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jpeds.2020.11.054","article-title":"Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy: a case series","volume":"231","author":"Chand","year":"2021","journal-title":"J. Pediatr."},{"key":"B40","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.3390\/ijms21093297","article-title":"New and developing therapies in spinal muscular atrophy. From genotype to phenotype to treatment and where do we stand?","volume":"21","author":"Chen","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/nm.2025","article-title":"Molecular signatures of disease brain endothelia provide new sites for CNS-directed enzyme therapy","volume":"15","author":"Chen","year":"2009","journal-title":"Nat. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1159\/000351153","article-title":"Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature","volume":"41","author":"Chi\u00f2","year":"2013","journal-title":"Neuroepidemiology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1159\/000078506","article-title":"Epidemiology of multiple system atrophy: a prevalence and pilot factor study in Aquitaine, France","volume":"23","author":"Chrysostome","year":"2004","journal-title":"Neuroepidemiology"},{"key":"B44","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1093\/brain\/awaa020","article-title":"Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson's disease","volume":"143","author":"Chu","year":"2020","journal-title":"Brain"},{"key":"B45","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ymthe.2019.08.018","article-title":"dCas9-based Scn1a gene activation restores inhibitory interneuron excitability and attenuates seizures in Dravet syndrome mice","volume":"8","author":"Colasante","year":"2020","journal-title":"Mol. Ther."},{"key":"B46","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13052-018-0562-1","article-title":"Enzyme replacement therapy: efficacy and limitations","volume":"44","author":"Concolino","year":"2018","journal-title":"Ital. J. Pediatrics"},{"key":"B47","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/sj.mt.6300357","article-title":"DNA-binding specificity is a major determinant of the activity and toxicity of zinc-finger nucleases","volume":"16","author":"Cornu","year":"2008","journal-title":"Mol. Ther"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1038\/s41431-020-0652-6","article-title":"AAV-mediated FOXG1 gene editing in human Rett primary cells","volume":"28","author":"Croci","year":"2020","journal-title":"Eur. J. Hum. Genet."},{"key":"B49","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/nature05017","article-title":"Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21","volume":"442","author":"Cruts","year":"2006","journal-title":"Nature"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1007\/s12325-019-00923-8","article-title":"Survival, motor function, and motor milestones: comparison of AVXS-101 relative to nusinersen for the treatment of infants with spinal muscular atrophy type 1","volume":"36","author":"Dabbous","year":"2019","journal-title":"Adv. Ther."},{"key":"B51","doi-asserted-by":"publisher","first-page":"e27221","DOI":"10.1371\/journal.pone.0027221","article-title":"Adeno-associated virus-mediated rescue of the cognitive defects in a mouse model for Angelman syndrome","volume":"6","author":"Daily","year":"2011","journal-title":"PLoS ONE"},{"key":"B52","doi-asserted-by":"publisher","first-page":"189r","DOI":"10.1126\/scitranslmed.3005708","article-title":"In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous","volume":"5","author":"Dalkara","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1093\/hmg\/ddy076","article-title":"Loss of CLN7 results in depletion of soluble lysosomal proteins and impaired mTOR reactivation","volume":"27","author":"Danyukova","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"B54","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.pcl.2015.03.010","article-title":"Spinal muscular atrophies","volume":"62","author":"Darras","year":"2015","journal-title":"Pediatr. Clin. N. Am."},{"key":"B55","doi-asserted-by":"publisher","first-page":"18003","DOI":"10.1038\/hgv.2018.3","article-title":"Identification of mutations in HEXA and HEXB in Sandhoff and Tay-Sachs diseases: a new large deletion caused by Alu elements in HEXA","volume":"5","author":"Dastsooz","year":"2018","journal-title":"Hum. Genome Var."},{"key":"B56","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nbt.3440","article-title":"Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain","volume":"34","author":"Deverman","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/s41556-018-0228-7","article-title":"CLN8 is an endoplasmic reticulum cargo receptor that regulates lysosome biogenesis","volume":"20","author":"di Ronza","year":"2018","journal-title":"Nat. Cell Biol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/sj.gt.3302684","article-title":"Administration-route and gender-independent long-term therapeutic correction of phenylketonuria (PKU) in a mouse model by recombinant adeno-associated virus 8 pseudotyped vector-mediated gene transfer","volume":"13","author":"Ding","year":"2006","journal-title":"Gene Ther."},{"key":"B60","doi-asserted-by":"publisher","first-page":"e0161660","DOI":"10.1371\/journal.pone.0161660","article-title":"Thirty years of orphan drug legislation and the development of drugs to treat rare seizure conditions: a cross sectional analysis","volume":"11","author":"D\u00f6ring","year":"2016","journal-title":"PLoS ONE"},{"key":"B61","doi-asserted-by":"publisher","first-page":"579062","DOI":"10.3389\/fnins.2020.579062","article-title":"Genome editing for CNS disorders","volume":"14","author":"Duarte","year":"2020","journal-title":"Front. Neurosci."},{"key":"B62","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1006\/mthe.2002.0690","article-title":"Five recombinant simian immunodeficiency virus pseudotypes lead to exclusive transduction of retinal pigmented epithelium in rat","volume":"6","author":"Duisit","year":"2002","journal-title":"Mol. Ther."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1111\/dmcn.14258","article-title":"Ethical issues with testing and treatment for Krabbe disease","volume":"61","author":"Ehmann","year":"2019","journal-title":"Dev. Med. Child Neurol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1056\/NEJMoa1700554","article-title":"Hematopoietic stem cell gene therapy for cerebral adrenoleukodystrophy","volume":"377","author":"Eichler","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/dmcn.14831","article-title":"UBE3A reinstatement as a disease-modifying therapy for Angelman syndrome","volume":"63","author":"Elgersma","year":"2021","journal-title":"Dev. Med. Child Neurol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.omtm.2019.04.001","article-title":"Pre-clinical safety an efficacy of lentiviral vector-mediated ex vivo stem cell gene therapy for the treatment of mucopolysaccharidosis IIIA","volume":"13","author":"Ellison","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B67","doi-asserted-by":"publisher","first-page":"e0225582","DOI":"10.1371\/journal.pone.0225582","article-title":"Clade F AAVHSCs cross the blood brain barrier and transduce the central nervous system in addition to peripheral tissues following intravenous administration in nonhuman primates","volume":"14","author":"Ellsworth","year":"2019","journal-title":"PLoS ONE"},{"key":"B68","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.virol.2012.10.003","article-title":"Memory of viral infections by CRISPR- Cas adaptive immune systems: acquisition of new information","volume":"434","author":"Fineran","year":"2012","journal-title":"Virology"},{"key":"B69","doi-asserted-by":"publisher","first-page":"103984","DOI":"10.1016\/j.jns.2019.10.322","article-title":"Intrathecal administration of AVXS-101 gene-replacement therapy (GRT) for spinal muscular atrophy type 2 (SMA1): phase 1\/2A study (strong)","author":"Finkel","year":"2019","journal-title":"J. Neurol. Sci."},{"key":"B70","unstructured":"One-time intrathecal (IT) administration of AVXS-101 IT gene-replacement therapy for spinal muscular atrophy: phase 1 study (STRONG)\n            FinkelR. S.\n            DayJ. W.\n            DarrasB. T.\n            KuntzN. L.\n            ConnolyA. M.\n            CrawfordT.\n          Neurology942020"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B72","doi-asserted-by":"publisher","first-page":"e25212","DOI":"10.4161\/rdis.25212","article-title":"Lifetime risk estimators in epidemiological studies of Krabbe disease: review and Monte Carlo comparison","volume":"30","author":"Foss","year":"2013","journal-title":"Rare Dis."},{"key":"B73","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1038\/mt.2013.211","article-title":"Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS","volume":"21","author":"Foust","year":"2013","journal-title":"Mol. Ther."},{"key":"B74","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13052-018-0565-y","article-title":"Gene therapy for mucopolysaccharidoses: in vivo and ex vivo approaches","volume":"44","author":"Fraldi","year":"2018","journal-title":"Ital. J. Pediatr."},{"key":"B75","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.omtm.2021.01.009","article-title":"Preclinical biodistribution, tropism, and efficacy of oligotropic AAV\/Olig001 in a mouse model of congenital white matter disease","volume":"20","author":"Francis","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B76","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1126\/science.175.4025.949","article-title":"Gene therapy for human genetic disease?","volume":"175","author":"Friedmann","year":"1972","journal-title":"Science"},{"key":"B77","doi-asserted-by":"publisher","first-page":"e000731","DOI":"10.1136\/bmjpo-2020-000731","article-title":"Multisystem comorbidities in classic Rett syndrome: a scoping review","volume":"4","author":"Fu","year":"2020","journal-title":"BMJ Paediatr. Open."},{"key":"B78","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.omtm.2017.04.007","article-title":"Development of a novel AAV gene therapy cassette with improved safety features and efficacy in a mouse model of Rett syndrome","volume":"5","author":"Gadalla","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B79","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2174\/1566523054065057","article-title":"New recombinant serotypes of AAV vectors","volume":"5","author":"Gao","year":"2005","journal-title":"Curr. Gene Ther."},{"key":"B80","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/978-1-4939-3271-9_30","article-title":"Gene therapy for the treatment of neurological disorders: metabolic disorders","volume":"1382","author":"Gessler","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"e90807","DOI":"10.1172\/jci.insight.90807","article-title":"Redirecting N-acetylaspartate metabolism in the central nervous system normalizes myelination and rescues Canavan disease","volume":"2","author":"Gessler","year":"2017","journal-title":"JCI. Insight"},{"key":"B82","doi-asserted-by":"publisher","first-page":"e8730","DOI":"10.15252\/emmm.201708730","article-title":"Brain-targeted stem cell gene therapy corrects mucopolysaccharidosis type II via multiple mechanisms","volume":"10","author":"Gleitz","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"B83","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1089\/hum.2016.109","article-title":"Direct intracranial injection of AAVrh8 encoding monkey \u03b2-N-acetylhexosaminidase causes neurotoxicity in the primate brain","volume":"28","author":"Golebiowski","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"B84","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/mt.2015.6","article-title":"Adenoassociated virus serotype 9-mediated gene therapy for X-linked adrenoleukodystrophy","volume":"23","author":"Gong","year":"2015","journal-title":"Mol. Ther"},{"key":"B85","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3389\/fonc.2019.00297","article-title":"Gene therapy leaves a vicious cycle","volume":"9","author":"Goswami","year":"2019","journal-title":"Front. Oncol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"6307","DOI":"10.1007\/s12035-017-0831-9","article-title":"Time is motor neuron: therapeutic window and its correlation with pathogenetic mechanisms in spinal muscular atrophy","volume":"55","author":"Govoni","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"517","DOI":"10.4155\/tde.10.50","article-title":"Viral vectors and delivery strategies for CNS gene therapy","volume":"1","author":"Gray","year":"2010","journal-title":"Ther. Deliv."},{"key":"B88","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1089\/hum.2017.163","article-title":"Adeno-associated virus gene therapy in a sheep model of Tay-Sachs disease","volume":"29","author":"Gray-Edwards","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"B89","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1126\/science.275.5300.657","article-title":"A general strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites","volume":"275","author":"Greisman","year":"1997","journal-title":"Science"},{"key":"B90","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1126\/science.1088547","article-title":"LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1","volume":"302","author":"Hacein-Bey-Abina","year":"2003","journal-title":"Science"},{"key":"B91","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3390\/biom11020189","article-title":"Mucopolysaccharidosis type I: current treatments, limitations, and prospects for improvement","volume":"11","author":"Hampe","year":"2021","journal-title":"Biomolecules"},{"key":"B92","doi-asserted-by":"publisher","first-page":"eaaz6100","DOI":"10.1126\/scitranslmed.aaz6100","article-title":"Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome","volume":"12","author":"Han","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"B93","doi-asserted-by":"publisher","first-page":"320","DOI":"10.106\/j.omtm.2019.10.007","article-title":"Selection of an efficient AAV vector for robust CNS transgene expression","volume":"15","author":"Hanlon","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B94","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/sj.gt.3302678","article-title":"Complete correction of hyperphenylalaninemia following liver-directed, recombinant AAV2\/8 vector-mediated gene therapy in murine phenylketonuria","volume":"13","author":"Harding","year":"2006","journal-title":"Gene Ther"},{"key":"B95","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1016\/j.ymgme.2018.12.163","article-title":"EMPOWERS: a phase 1\/2 clinical trial of SB-318 ZFN-mediated in vivo human genome editing for treatment of MPS I (Hurler syndrome)","volume":"126","author":"Harmatz","year":"2019","journal-title":"Mol. Genet. Metab"},{"key":"B96","doi-asserted-by":"publisher","first-page":"107970","DOI":"10.1016\/j.neuropharm.2020.107970","article-title":"Personalized medicine in genetic epilepsies \u2013 possibilities, challenges, and new frontiers","volume":"172","author":"Helbig","year":"2020","journal-title":"Neuropharmacology"},{"key":"B97","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1038\/mt.2014.135","article-title":"Intrathecal gene therapy corrects CNS pathology in a feline model of mucopolysaccharidosis I","volume":"22","author":"Hinderer","year":"2014","journal-title":"Mol. Ther."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/mt.2015.99","article-title":"Neonatal systemic AAV induces tolerance to CNS gene therapy in MPS I dogs and nonhuman primates","volume":"23","author":"Hinderer","year":"2015","journal-title":"Mol. Ther."},{"key":"B99","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1089\/hum.2018.015","article-title":"Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration and adeno-associated virus vector expressing human SMN","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"B100","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1089\/hum.2016.087","article-title":"Adeno-associated virus-based gene therapy for CNS diseases","volume":"27","author":"Hocquemiller","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"B101","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1089\/hum.2020.038","article-title":"Gene therapy targeting the inner retina rescues the retinal phenotype in a mouse model of CLN3 Batten disease","volume":"31","author":"Holthaus","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"B102","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.ymthe.2018.01.018","article-title":"The Neurotropic properties of AAV-PHP.B are limited to C57BL\/6J mice","volume":"26","author":"Hordeaux","year":"2018","journal-title":"Mol. Ther."},{"key":"B103","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.ymthe.2019.02.013","article-title":"The GPI-linked protein LY6A drives AAV-PHP.B transport across the blood-brain barrier","volume":"27","author":"Hordeaux","year":"2019","journal-title":"Mol. Ther."},{"key":"B104","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1152\/nips.01343.2001","article-title":"Gene therapy of hematopoietic stem cells: strategies for improvement","volume":"17","author":"Hossle","year":"2002","journal-title":"News Physiol. Sci."},{"key":"B105","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.neuron.2019.02.017","article-title":"Therapeutic AAV gene transfer to the nervous system: a clinical reality","volume":"101","author":"Hudry","year":"2019","journal-title":"Neuron"},{"key":"B106","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1002\/ana.25674","article-title":"Antisense oligonucleotide reverses leukodystrophy in Canavan disease mice","volume":"87","author":"Hull","year":"2020","journal-title":"Ann. Neurol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.omtn.2018.04.015","article-title":"Translating SOD1 gene silencing toward the clinic: a highly efficacious, off-target-free, and biomarker-supported strategy for ALS","volume":"12","author":"Iannitti","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B108","doi-asserted-by":"publisher","first-page":"724","DOI":"10.3389\/fphar.2019.00724","article-title":"Gene therapy tools for brain diseases","volume":"10","author":"Ingusci","year":"2019","journal-title":"Front. Pharmacol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/s41583-018-0006-3","article-title":"Rett syndrome: insights into genetic, molecular and circuit mechanisms","volume":"19","author":"Ip","year":"2018","journal-title":"Nat. Rev. Neurosci."},{"key":"B110","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/med.21528","article-title":"Riluzole and edaravone: a tale of two amyotrophic lateral sclerosis drugs","volume":"39","author":"Jaiswal","year":"2019","journal-title":"Med. Res. Rev."},{"key":"B111","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1089\/104303402760128612","article-title":"Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain","volume":"13","author":"Janson","year":"2002","journal-title":"Hum. Gene Ther."},{"key":"B112","doi-asserted-by":"publisher","first-page":"a024240","DOI":"10.1101\/cshperspect.a024240","article-title":"Huntington's disease: mechanisms of pathogenesis and therapeutic strategies","volume":"7","author":"Jimenez-Sanchez","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"B113","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41582-019-0138-8","article-title":"Therapeutic landscape for Batten disease: current treatments and future prospects","volume":"15","author":"Johnson","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ymthe.2020.09.033","article-title":"AAV9 gene therapy increases lifespan and treats pathological and behavioral abnormalities in a mouse model of CLN8-Batten disease","volume":"29","author":"Johnson","year":"2021","journal-title":"Mol. Ther."},{"key":"B115","doi-asserted-by":"publisher","first-page":"12267","DOI":"10.1002\/jcp.27972","article-title":"CRISPR\/Cas9 technology as a potent molecular tool for gene therapy","volume":"234","author":"Karimian","year":"2018","journal-title":"J. Cell Physiol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.prrv.2018.03.003","article-title":"New and developing therapies in spinal muscular atrophy","volume":"28","author":"Kariyawasam","year":"2018","journal-title":"Paediatr. Respir. Rev."},{"key":"B117","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s40478-019-0769-4","article-title":"Cross-examining candidate genes implicated in multiple system atrophy","volume":"7","author":"Katzeff","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"B118","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1146\/annurev-virology-092818-015530","article-title":"Recombinant adeno-associated virus gene therapy in light of luxturna (and zolgensma and glybera): where are we, and how did we get here?","volume":"6","author":"Keeler","year":"2019","journal-title":"Annu. Rev. Virol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/j.bbadis.2012.03.012","article-title":"X-linked adrenoleukodystrophy: clinical, metabolic, genetic and pathophysiological aspects","volume":"1822","author":"Kemp","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"B120","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/humu.1227","article-title":"ABCD1 mutations and the X-linked adrenoleukodystrophy mutation database: role in diagnosis and clinical correlations","volume":"18","author":"Kemp","year":"2001","journal-title":"Hum. Mutation"},{"key":"B121","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","article-title":"Patient-customized oligonucleotide therapy for a rare genetic disease","volume":"381","author":"Kim","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B122","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.3390\/pharmaceutics12121216","article-title":"Current status and challenges associated with CNS-targeted gene delivery across the BBB","volume":"12","author":"Kimura","year":"2020","journal-title":"Pharmaceutics"},{"key":"B123","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/d41573-021-00088-6","article-title":"Double setback for ASO trials in Huntington disease","volume":"20","author":"Kingwell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"B124","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1182\/blood-2020-141762","article-title":"Ex-vivo autologous stem cell gene therapy clinical trial for mucopolysaccharidosis type IIIA: trial in progress - NCT04201405","volume":"136","author":"Kinsella","year":"2020","journal-title":"Blood."},{"key":"B125","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/s0169-328x(02)00490-4","article-title":"Aspartoacylase is restricted to myelin synthesizing cells in the CNS: therapeutic implications for Canavan disease","volume":"107","author":"Kirmani","year":"2002","journal-title":"Mol. Brain Res"},{"key":"B126","first-page":"682","article-title":"CLN2 disease (classic late infantile neuronal ceroid lipofuscinosis)","volume":"13","author":"Kohlsch\u00fctter","year":"2016","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"B127","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/0888-7543(91)90470-y","article-title":"Mapping and direct visualization of a region specific viral DNA integration site on chromosome 19q13qter","volume":"10","author":"Kotin","year":"1991","journal-title":"Genomics"},{"key":"B128","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1073\/pnas.87.6.2211","article-title":"Site-specific integration by adeno-associated virus","volume":"87","author":"Kotin","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"B129","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3390\/diagnostics10030172","article-title":"Diagnosis of mucopolysaccharidoses","volume":"10","author":"Kubaski","year":"2020","journal-title":"Diagnostics"},{"key":"B130","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13023-018-0766-x","article-title":"Consensus guidelines for newborn screening, diagnosis, and treatment of infantile Krabbe disease","volume":"13","author":"Kwon","year":"2018","journal-title":"Orphanet. J. Rare Dis"},{"key":"B131","doi-asserted-by":"publisher","first-page":"170216","DOI":"10.1098\/rsob.170216","article-title":"Rett syndrome: a neurological disorder with metabolic components","volume":"8","author":"Kyle","year":"2018","journal-title":"Open Biol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.ymthe.2018.03.002","article-title":"Dose-dependent prevention of metabolic and neurologic disease in murine MPS II by ZFN-mediated in vivo genome editing","volume":"26","author":"Laoharawee","year":"2018","journal-title":"Mol. Ther."},{"key":"B133","doi-asserted-by":"publisher","first-page":"S91","DOI":"10.1016\/j.ymgme.2018.12.227","article-title":"AAV gene therapy LYS-SAF302 demonstrates widespread sulfamidase distribution in primate brain and correction of disease pathology in MPS IIIA mice","volume":"126","author":"Laufer","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"B134","doi-asserted-by":"publisher","first-page":"6213","DOI":"10.3390\/ijms21176213","article-title":"GM2 gangliosidoses: clinical features, pathophysiological aspects, and current therapies","volume":"21","author":"Leal","year":"2020","journal-title":"J. Mol. Sci."},{"key":"B135","doi-asserted-by":"publisher","first-page":"101123","DOI":"10.1016\/j.isci.2020.101123","article-title":"Rare genetic diseases: nature's experiments on human development","volume":"23","author":"Lee","year":"2020","journal-title":"Science"},{"key":"B136","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.nbd.2011.09.014","article-title":"Viral vectors for gene delivery to the central nervous system","volume":"48","author":"Lentz","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"B137","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/1531-8249(200007)48:1<27::aid-ana6>3.0.co;2-6","article-title":"Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease","volume":"48","author":"Leone","year":"2000","journal-title":"Ann. Neurol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"165r","DOI":"10.1126\/scitranslmed.3003454","article-title":"Long-term follow-up after gene therapy for Canavan disease","volume":"14","author":"Leone","year":"2012","journal-title":"Sci. Transl. Med"},{"key":"B139","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1006\/mgme.1999.2880","article-title":"Human phenylalanine hydroxylase gene expression in kidney and other nonhepatic tissues","volume":"67","author":"Lichter-Konecki","year":"1999","journal-title":"Mol. Genet. Metab"},{"key":"B140","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11011-020-00630-2","article-title":"Crossing the blood-brain barrier with AAV vectors","volume":"36","author":"Liu","year":"2021","journal-title":"Metab. Brain Dis."},{"key":"B141","doi-asserted-by":"publisher","first-page":"165772","DOI":"10.1016\/j.bbadis.2020.165772","article-title":"Experimental gene therapies for the NCLs","volume":"1866","author":"Liu","year":"2020","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"B142","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1038\/nm.1876","article-title":"Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium","volume":"14","author":"Lloyd-Evans","year":"2008","journal-title":"Nat. Med."},{"key":"B143","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.pediatrneurol.2019.05.005","article-title":"Impact of age and motor function in a phase 1\/2A study of infants with SMA type 1 receiving single-dose gene replacement therapy","volume":"98","author":"Lowes","year":"2019","journal-title":"Pediatr. Neurol."},{"key":"B144","doi-asserted-by":"publisher","first-page":"632522","DOI":"10.3389\/fnins.2021.632522","article-title":"In vivo genome editing therapeutic approaches for neurological disorders: where are we in the translational pipeline?","volume":"15","author":"Lubroth","year":"2021","journal-title":"Front. Neurosci."},{"key":"B145","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1006\/mthe.2002.0681","article-title":"Efficient transduction of liver and muscle after in utero injection of lentiviral vectors with different pseudotypes","volume":"6","author":"MacKenzie","year":"2002","journal-title":"Mol. Ther."},{"key":"B146","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.stem.2007.10.001","article-title":"Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood","volume":"1","author":"Majeti","year":"2007","journal-title":"Cell Stem Cell"},{"key":"B147","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/nrmicro3569","article-title":"An updated evolutionary classification of CRISPR\u2013Cas systems","volume":"13","author":"Makarova","year":"2015","journal-title":"Nat. Rev. Microbiol."},{"key":"B148","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41579-019-0299-x","article-title":"Evolutionary classification of CRISPR\u2013Cas systems: a burst of class 2 and derived variants","volume":"18","author":"Makarova","year":"2020","journal-title":"Nat. Rev. Microbiol."},{"key":"B149","doi-asserted-by":"publisher","first-page":"1601484","DOI":"10.1080\/20016689.2019.1601484","article-title":"Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients","volume":"7","author":"Malone","year":"2019","journal-title":"J. Market Access Health Policy"},{"key":"B150","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1089\/hum.2019.217","article-title":"In vivo gene therapy for mucopolysaccharidosis type III (Sanfilippo syndrome): a new treatment horizon","volume":"30","author":"Marc\u00f3","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"B151","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s40265-017-0771-8","article-title":"Cerliponase alfa: first global approval","volume":"77","author":"Markham","year":"2017","journal-title":"Drugs"},{"key":"B152","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.001","article-title":"Targeting RNA-mediated toxicity in C9orf72 ALS and\/or FTD by RNAi-based gene therapy","volume":"16","author":"Martier","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B153","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1055\/s-0037-1601324","article-title":"Lennox-Gastaut syndrome: a state of the art review","volume":"48","author":"Mastrangelo","year":"2017","journal-title":"Neuropediatrics"},{"key":"B154","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"key":"B155","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.3389\/fnins.2019.01310","article-title":"ALS genetics, mechanisms, and therapeutics: where are we now?","volume":"13","author":"Mejzini","year":"2019","journal-title":"Front. Neurosci."},{"key":"B156","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B157","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","article-title":"Current clinical applications of in vivo gene therapy with AAVs","volume":"29","author":"Mendell","year":"2021","journal-title":"Mol. Ther."},{"key":"B158","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B159","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.celrep.2015.04.007","article-title":"Efficient CRISPR-Cas9-mediated generation of knockin human pluripotent stem cells lacking undesired mutations at the targeted locus","volume":"11","author":"Merkle","year":"2015","journal-title":"Cell Reports"},{"key":"B160","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1002\/j.1460-2075.1985.tb03825.x","article-title":"Repetitive zinc-binding domains in the protein transcription factor IIIA from Xenopus oocytes","volume":"4","author":"Miller","year":"1985","journal-title":"EMBO J."},{"key":"B161","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nbt.1755","article-title":"A TALE nuclease architecture for efficient genome editing","volume":"29","author":"Miller","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"B162","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1034\/j.1600-065X.2003.00060.x","article-title":"The role of DNA breaks in genomic instability and tumorigenesis","volume":"194","author":"Mills","year":"2003","journal-title":"Immunol. Rev."},{"key":"B163","doi-asserted-by":"publisher","first-page":"319","DOI":"10.2174\/156652310793180706","article-title":"AAV's anatomy: roadmap for optimizing vectors for translational success","volume":"10","author":"Mitchell","year":"2010","journal-title":"Curr. Gene Ther."},{"key":"B164","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1016\/j.ymthe.2018.07.015","article-title":"Longitudinal in vivo monitoring of the CNS demonstrates the efficacy of gene therapy in a sheep model of CLN5 Batten disease","volume":"26","author":"Mitchell","year":"2018","journal-title":"Mol. Ther."},{"key":"B165","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.stem.2017.10.010","article-title":"Hematopoietic stem cell gene therapy \u2013 progress and lessons learned","volume":"21","author":"Morgan","year":"2017","journal-title":"Cell Stem Cell"},{"key":"B166","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1056\/NEJMoa2005056","article-title":"SOD1 suppression with adeno-associated virus and microRNA in familial ALS","volume":"383","author":"Mueller","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B167","doi-asserted-by":"publisher","first-page":"S104","DOI":"10.1016\/j.ymgme.2018.12.263","article-title":"CHAMPIONS: a phase 1\/2 clinical trial with dose escalation of SB-913 ZFN-mediated in vivo human genome editing for treatment of MPS II (Hunter syndrome)","volume":"126","author":"Muenzer","year":"2019","journal-title":"Mol. Genet. Metab"},{"key":"B168","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/d41573-020-00027-x","article-title":"N-of-1 drugs push biopharma frontiers","volume":"19","author":"Mullard","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"B169","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/s0960-8966(06)80015-5","article-title":"International SMA consortium meeting. (26-28 June) 1992, Bonn, Germany)","volume":"2","author":"Munsat","year":"1992","journal-title":"Neuromuscul. Disord."},{"key":"B170","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1126\/science.272.5259.263","article-title":"In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector","volume":"272","author":"Naldini","year":"1996","journal-title":"Science"},{"key":"B171","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1038\/s41587-020-0642-9","article-title":"High-dose AAV gene therapy deaths","volume":"38","year":"2020","journal-title":"Nat. Biotechnol"},{"key":"B172","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41587-020-0741-7","article-title":"A long-term study of gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells","volume":"39","author":"Nguyen","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"B173","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1016\/j.ymthe.2020.03.018","article-title":"A highly efficacious PS gene editing system corrects metabolic and neurological complications of mucopolysaccharidosis type I","volume":"28","author":"Ou","year":"2020","journal-title":"Mol. Ther."},{"key":"B174","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1523\/JNEUROSCI.2676-05.2006","article-title":"Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis","volume":"26","author":"Passini","year":"2006","journal-title":"J. Neurosci."},{"key":"B175","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41434-019-0085-4","article-title":"AAV9 vector: a novel modality in gene therapy for spinal muscular atrophy","volume":"26","author":"Pattali","year":"2019","journal-title":"Gene Ther."},{"key":"B176","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1126\/science.2028256","article-title":"Zinc finger-DNA recognition: crystal structure of a Zif268-DNA complex at 2.1 A","volume":"252","author":"Pavletich","year":"1991","journal-title":"Science"},{"key":"B177","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1007\/s10072-020-04600-5","article-title":"West syndrome: a comprehensive review","volume":"41","author":"Pavone","year":"2020","journal-title":"Neurol. Sci."},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.18103\/mra.v8i2.2045","article-title":"A cure for Sanfilippo syndrome? A summary of current therapeutic approaches and their promise","volume":"8","author":"Pearse","year":"2020","journal-title":"Med. Res. Arch."},{"key":"B179","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s10545-017-0052-4","article-title":"Gene therapy for lysosomal storage disorders: recent advances for metachromatic leukodystrophy and mucopolysaccharidosis","volume":"40","author":"Penati","year":"2017","journal-title":"J. Inherit. Metab. Dis."},{"key":"B180","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/mdc3.12145","article-title":"Current concepts in the treatment of multiple system atrophy","volume":"2","author":"Perez-Lloret","year":"2015","journal-title":"Mov. Disord. Clin. Pract."},{"key":"B181","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.tips.2021.03.004","article-title":"Delivering AAV to the central nervous and sensory systems","volume":"42","author":"Peters","year":"2021","journal-title":"Trends Pharmacol. Sci."},{"key":"B182","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1089\/hum.2012.015","article-title":"Correction of brain oligodendrocytes by AAVrh.10 intracerebral gene therapy in metachromatic leukodystrophy mice","volume":"23","author":"Piguet","year":"2012","journal-title":"Hum. Gene Ther"},{"key":"B183","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3390\/ijms21020500","article-title":"Genome editing for mucopolysaccharidoses","volume":"21","author":"Poletto","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B184","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1590\/1678-4685-GMB-2018-0159","article-title":"Lysosomal diseases: overview on current diagnosis and treatment","volume":"42","author":"Poswar","year":"2019","journal-title":"Genet. Mol. Biol."},{"key":"B185","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1002\/mds.25075","article-title":"The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis","volume":"27","author":"Pringsheim","year":"2012","journal-title":"Mov. Disord"},{"key":"B186","doi-asserted-by":"publisher","first-page":"105","DOI":"10.34172\/bi.2020.13","article-title":"Conditions for combining gene therapy with bone marrow transplantation in murine Krabbe disease","volume":"10","author":"Rafi","year":"2020","journal-title":"Bioimpacts"},{"key":"B187","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/nmeth0508-374","article-title":"Unexpected failure rates for modular assembly of engineered zinc fingers","volume":"5","author":"Ramirez","year":"2008","journal-title":"Nat. Methods"},{"key":"B188","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.18553\/jmcp.2018.24.12-a.s3","article-title":"Gene therapy for spinal muscular atrophy: an emerging treatment option for a devastating disease","volume":"24","author":"Rao","year":"2018","journal-title":"J. Manag. Care Spec. Pharm"},{"key":"B189","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ymgme.2003.08.016","article-title":"Fatal systemic inflammatory syndrome in a ornithine transcarbarmylase deficient patient following adenoviral gene transfer","volume":"80","author":"Raper","year":"2003","journal-title":"Mol. Genet. Metab."},{"key":"B190","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.jval.2015.05.008","article-title":"Rare disease terminology and definitions\u2014a systematic global review: report of the ISPOR rare disease special interest group","volume":"18","author":"Richter","year":"2015","journal-title":"Value Health"},{"key":"B191","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.1093\/hmg\/ddu169","article-title":"Defining the therapeutic window in a severe animal model of spinal muscular atrophy","volume":"23","author":"Robbins","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"B192","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1093\/hmg\/ddx058","article-title":"Disease correction by AAV-mediated gene therapy in a new mouse model of mucopolysaccharidosis type IIID","volume":"26","author":"Roca","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"B193","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3233\/JHD-200002","article-title":"Huntington's disease clinical trials corner: April 2020","volume":"9","author":"Rodrigues","year":"2020","journal-title":"J. Hunt. Dis"},{"key":"B194","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1002\/jnr.23792","article-title":"Gene therapy for metachromatic leukodystrophy","volume":"94","author":"Rosenberg","year":"2016","journal-title":"J. Neurosci. Res"},{"key":"B195","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1089\/hum.2012.052","article-title":"Safety study of adeno-associated virus serotype 2-mediated human acid sphingomyelinase expression in the nonhuman primate brain","volume":"23","author":"Salegio","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"B196","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1128\/microbiolspec.MDNA3-0052-2014","article-title":"Adeno-associated virus as a mammalian DNA vector","author":"Salganik","year":"2015","journal-title":"Microbiol. Spectr."},{"key":"B197","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1055\/s-0040-1701694","article-title":"Changing landscape of Dravet syndrome management: an overview","volume":"51","author":"Samanta","year":"2020","journal-title":"Neuropediatrics"},{"key":"B198","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1126\/scitranslmed.aat3738","article-title":"Adeno-associated viral vector serotype 9-based gene therapy for Niemann-Pick disease type A","volume":"21","author":"Samaranch","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"B199","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S1474-4422(20)30217-30219","article-title":"Advances in understanding of Rett syndrome and MECP2 duplication syndrome: prospects for future therapies","volume":"19","author":"Sandweiss","year":"2020","journal-title":"Lancet Neurol"},{"key":"B200","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/s0387-7604(88)80075-5","article-title":"Neuronal ceroid-lipofuscinoses in childhood","volume":"10","author":"Santavuori","year":"1988","journal-title":"Brain Dev."},{"key":"B201","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/s0092-8674(02)00864-4","article-title":"HIV-1integration in the human genome favors active genes and local hotspots","volume":"110","author":"Schr\u00f6der","year":"2002","journal-title":"Cell"},{"key":"B202","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/cpt.1639","article-title":"Regulators' advice can make a difference: European Medicines Agency approval of Zynteglo for beta thalassemia","volume":"107","author":"Schuessler-Lenz","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"B203","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1056\/NEJMoa1712649","article-title":"Study of intraventricular cerliponase alfa for CLN2 disease","volume":"378","author":"Schulz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B204","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1089\/humc.2017.010","article-title":"Persistent expression of dopamine-synthesizing enzymes 15 years after gene transfer in a primate model of Parkinson's disease","volume":"28","author":"Sehara","year":"2017","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"B205","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S0140-6736(16)30374-9","article-title":"Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1\/2 trial","volume":"388","author":"Sessa","year":"2016","journal-title":"Lancet"},{"key":"B206","doi-asserted-by":"publisher","first-page":"90","DOI":"10.2174\/1566523218666180404155759","article-title":"Genetics and gene therapy in Hunter disease","volume":"18","author":"Sestito","year":"2018","journal-title":"Curr. Gene Ther."},{"key":"B207","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2353\/ajpath.2010.091267271","article-title":"CNS-expressed cathepsin D prevents lymphopenia in a murine model of congenital neuronal ceroid lipofuscinosis","volume":"177","author":"Shevtsova","year":"2010","journal-title":"Am. J. Pathol."},{"key":"B208","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/aps.2017.2","article-title":"Therapeutic gene editing: delivery and regulatory perspectives","volume":"38","author":"Shim","year":"2017","journal-title":"Acta Pharmacol. Sin"},{"key":"B209","doi-asserted-by":"publisher","first-page":"E5920","DOI":"10.1073\/pnas.1701832114","article-title":"Synergistic effects of treating the spinal cord and brain in CLN1 disease","volume":"114","author":"Shyng","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"B210","first-page":"1","article-title":"Adenoviral vector-based vaccines and gene therapies: current status and future prospects","volume-title":"Adenoviruses.","author":"Sing","year":"2018"},{"key":"B211","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.omtm.2017.04.006","article-title":"Improved MECP2 gene therapy extends the survival of MeCP2-null mice without apparent toxicity after intracisternal delivery","volume":"5","author":"Sinnett","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev"},{"key":"B212","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1523\/JNEUROSCI.1143-18.2019","article-title":"Epilepsy gene therapy using an engineered potassium channel","volume":"39","author":"Snowball","year":"2019","journal-title":"J. Neurosci."},{"key":"B213","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.ymthe.2020.01.006","article-title":"Adenovirus-antibody complexes contributed to lethal systemic inflammation in a gene therapy trial","volume":"28","author":"Somanathan","year":"2020","journal-title":"Mol. Ther"},{"key":"B214","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/sj.mt.6300049","article-title":"Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector","volume":"15","author":"Sondhi","year":"2007","journal-title":"Mol. Ther."},{"key":"B215","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1089\/hgtb.2012.120","article-title":"Long-term expression and safety of administration of AAVrh.10hCLN2 to the brain of rats and nonhuman primates for the treatment of late infantile neuronal ceroid lipofuscinosis","volume":"23","author":"Sondhi","year":"2012","journal-title":"Hum. Gene Ther. Methods"},{"key":"B216","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3171\/2010.4.PEDS09507","article-title":"Gene therapy for late infantile neuronal ceroid lipofuscinosis: neurosurgical considerations","volume":"6","author":"Souweidane","year":"2010","journal-title":"J. Neurosurg. Pediatr."},{"key":"B217","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s40265-020-01440-7","article-title":"Neuronal ceroid lipofuscinosis: potential for targeted therapy","volume":"81","author":"Specchio","year":"2021","journal-title":"Drugs"},{"key":"B218","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1080\/13543784.2020.1743678","article-title":"Epilepsy: key experimental therapeutics in early clinical development","volume":"29","author":"Steriade","year":"2020","journal-title":"Exp. Opin. Invest. Drugs"},{"key":"B219","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3389\/fnmol.2020.603409","article-title":"Gene therapy vector encoding neuropeptide Y and its receptor Y2 for future treatment of epilepsy: preclinical data in rats","volume":"13","author":"Szczygiel","year":"2020","journal-title":"Front. Mol. Neurosci."},{"key":"B220","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.ymthe.2019.11.012","article-title":"A safe and reliable technique for CNS delivery of AAV vectors in the cisterna magna","volume":"28","author":"Taghain","year":"2020","journal-title":"Mol. Ther"},{"key":"B221","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/S1474-4422(17)30169-2","article-title":"Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1\/2 clinical trial","volume":"16","author":"Tardieu","year":"2017","journal-title":"Lancet Neurol."},{"key":"B222","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1089\/hum.2013.238","article-title":"Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I\/II trial","volume":"25","author":"Tardieu","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"B223","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/01.GIM.0000078027.83236.49","article-title":"Can mucopolysaccharidosis type I disease severity be predicted based on a patient's genotype? A comprehensive review of the literature","volume":"5","author":"Terlato","year":"2003","journal-title":"Genet. Med."},{"key":"B224","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1177\/1091581820966315","article-title":"Safety assessment of AAV2-hGDNF administered via intracerebral injection in rats for treatment of Parkinson's disease","volume":"40","author":"Terse","year":"2021","journal-title":"Int. J. Toxicol."},{"key":"B225","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/gt.2009.46","article-title":"Independent and high-level dual-gene expression in adult stem-progenitor cells from a single lentiviral vector","volume":"16","author":"Tian","year":"2009","journal-title":"Gene Ther."},{"key":"B226","doi-asserted-by":"publisher","first-page":"17684","DOI":"10.1038\/s41598-019-53995-5","article-title":"Pre-diagnosing and managing patients with GM1 gangliosidosis and related disorders by the evaluation of GM1 ganglioside content","volume":"9","author":"Tonin","year":"2019","journal-title":"Scient. Rep"},{"key":"B227","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ymthe.2020.11.020","article-title":"Update on clinical ex vivo hematopoietic stem cell gene therapy for inherited monogenic disease","volume":"29","author":"Tucci","year":"2021","journal-title":"Mol. Ther."},{"key":"B228","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/jdn.10003","article-title":"X-linked adrenoleukodystrophy: pathology, pathophysiology, diagnostic testing, newborn screening and therapies","volume":"80","author":"Turk","year":"2020","journal-title":"Int. J. Dev. Neurosci."},{"key":"B229","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/jnc.15168","article-title":"Recent advances in gene therapy for neurodevelopmental disorders with epilepsy","volume":"157","author":"Turner","year":"2021","journal-title":"J. Neurochem."},{"key":"B230","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/nrg2842","article-title":"Genome editing with engineered zinc finger nucleases","volume":"11","author":"Urnov","year":"2010","journal-title":"Nat. Rev. Genet."},{"key":"B231","doi-asserted-by":"publisher","first-page":"448","DOI":"10.3389\/fnmol.2018.00448","article-title":"UBE3A and its link with autism","volume":"11","author":"Vatsa","year":"2018","journal-title":"Front. Mol. Neurosci."},{"key":"B232","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00401-017-1784-9","article-title":"Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy","volume":"135","author":"von Jonquieres","year":"2018","journal-title":"Acta Neuropathol."},{"key":"B233","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41431-019-0508-0","article-title":"Estimating cumulative point prevalence of rare disease: analysis of the Orphanet database","volume":"28","author":"Wakap","year":"2020","journal-title":"Eur. J. Hum. Genet."},{"key":"B234","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1177\/0883073807305788","article-title":"Consensus statement for standard of care in spinal muscular atrophy","volume":"22","author":"Wang","year":"2007","journal-title":"J. Child Neurol."},{"key":"B235","first-page":"151","article-title":"State-of-the-art human gene therapy: Part II. Gene therapy strategies and applications","volume":"18","author":"Wang","year":"2014","journal-title":"Discov. Med."},{"key":"B236","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1089\/hum.2015.087","article-title":"Adenovirus-mediated somatic genome editing of Pten by CRISPR\/Cas9 in mouse liver in spite of Cas9-specific immune responses","volume":"26","author":"Wang","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"B237","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"B238","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.cell.2020.03.023","article-title":"CRISPR-based therapeutic genome editing: strategies and in vivo delivery by AAV vectors","volume":"181","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"B239","doi-asserted-by":"publisher","first-page":"14066","DOI":"10.1038\/mtm.2014.66","article-title":"Re-examination of regulatory opinions in Europe: possible contribution for the approval of the first gene therapy product Glybera","volume":"2","author":"Watanabe","year":"2015","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B240","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/sj.gt.3302735","article-title":"Intrathecal administration of AAV vectors for the treatment of lysosomal storage in the brains of MPS I mice","volume":"13","author":"Watson","year":"2006","journal-title":"Gene Ther."},{"key":"B241","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.ymgme.2009.10.184","article-title":"The psychology and neuropathology of phenylketonuria","volume":"99","author":"White","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"B242","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.omtm.2020.12.014","article-title":"Intracranial delivery of AAV9 gene therapy partially prevents retinal degeneration and visual deficits in CLN6-Batten disease mice","volume":"5","author":"White","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B243","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/nature10886","article-title":"RNA-guided genetic silencing systems in bacteria and archaea","volume":"482","author":"Wiedenheft","year":"2012","journal-title":"Nature"},{"key":"B244","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1136\/jnnp-2019-321506","article-title":"Abnormal coagulation paramters are a common non-neuromuscular feature in patients with spinal muscular atrophy","volume":"91","author":"Wijngaarde","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B245","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/310476a0","article-title":"Introduction of new genetic material into pluripotent haematopoietic stem cells of the mouse","volume":"310","author":"Williams","year":"1984","journal-title":"Nature"},{"key":"B246","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ymgme.2008.12.016","article-title":"Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency","volume":"96","author":"Wilson","year":"2009","journal-title":"Mol. Genet. Metab"},{"key":"B247","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1089\/hum.2015.170","article-title":"A preclinical study evaluating AAVrh10-based gene therapy for Sanfilippo syndrome","volume":"27","author":"Winner","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"B248","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/306151a0","article-title":"Cloned human phenylalanine hydroxylase gene allows prenatal diagnosis and carrier detection of classical phenylketonuria","volume":"306","author":"Woo","year":"1983","journal-title":"Nature"},{"key":"B249","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.omtm.2018.10.011","article-title":"Efficacy of a bicistronic vector for correction of Sandhoff disease in a mouse model","volume":"12","author":"Woodley","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B250","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1089\/hum.2008.022","article-title":"Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA","volume":"19","author":"Worgall","year":"2008","journal-title":"Hum. Gene Ther."},{"key":"B251","doi-asserted-by":"publisher","first-page":"104954","DOI":"10.1016\/j.nbd.2020.104954","article-title":"CRISPR\/dCas9-based Scn1a gene activation in inhibitory neurons ameliorates epileptic and behavioral phenotypes of Dravet syndrome model mice","volume":"141","author":"Yamagata","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"B252","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/mt.2014.68","article-title":"Global CNS transduction of adult mice by intravenously delivered rAAVrh.8 and rAAVrh.10 and nonhuman primates by rAAVrh.10","volume":"22","author":"Yang","year":"2014","journal-title":"Mol. Ther."},{"key":"B253","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1038\/s41556-019-0425-z","article-title":"Advances in genome editing through control of DNA repair pathways","volume":"21","author":"Yeh","year":"2019","journal-title":"Nat. Cell Biol"},{"key":"B254","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.gene","article-title":"Canavan disease: an Arab scenario","volume":"560","author":"Zayed","year":"2015","journal-title":"Gene"},{"key":"B255","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1089\/humc.2014.139","article-title":"Intracerebral gene therapy using AAVrh-10-hARSA recombinant vector to treat patients with early-onset forms of metachromatic leukodystrophy: preclinical feasibility and safety assessments in nonhuman primates","volume":"26","author":"Zerah","year":"2015","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"B256","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/nbt.1775","article-title":"Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription","volume":"29","author":"Zhang","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"B257","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1006\/mthe.2001.0469","article-title":"Multigene lentiviral vectors based on different and translational control","volume":"4","author":"Zhu","year":"2001","journal-title":"Mol. Ther."},{"key":"B258","doi-asserted-by":"publisher","first-page":"9873","DOI":"10.1128\/JVI.72.12.9873-9880.1998","article-title":"Self-inactivating lentivirus vector for safe and efficient in vivo gene therapy","volume":"72","author":"Zufferey","year":"1998","journal-title":"J. Virol."}],"container-title":["Frontiers in Molecular Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnmol.2021.695937\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T07:22:21Z","timestamp":1633591341000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnmol.2021.695937\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,6]]},"references-count":258,"alternative-id":["10.3389\/fnmol.2021.695937"],"URL":"https:\/\/doi.org\/10.3389\/fnmol.2021.695937","relation":{},"ISSN":["1662-5099"],"issn-type":[{"value":"1662-5099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,6]]},"article-number":"695937"}}